Tekla Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Tekla Capital Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$2.6M	Sell	67,506 -16,208	-19%	-$644K	0.1%	104
2023 Q1	$3M	Hold	83,714	–	–	0.11%	101
2022 Q4	$3.3M	Buy	83,714 +21,981	+36%	+$800K	0.12%	93
2022 Q3	$2.23M	Buy	61,733 +32,023	+108%	+$1.15M	0.09%	110
2022 Q2	$904K	Buy	+29,710	New	+$899K	0.04%	137
2021 Q4	–	Sell	-169,030	Closed	-$2.58M	–	183
2021 Q3	$2.58M	Hold	169,030	–	–	0.08%	129
2021 Q2	$3.15M	Buy	169,030 +3,132	+2%	+$57.7K	0.1%	138
2021 Q1	$2.97M	Buy	+165,898	New	+$2.81M	0.1%	149
2020 Q1	–	Sell	-96,961	Closed	-$1.27M	–	223
2019 Q4	$1.27M	Buy	+96,961	New	+$1.02M	0.05%	175
2018 Q3	–	Sell	-163,819	Closed	-$1.51M	–	214
2018 Q2	$1.51M	Sell	163,819 -116,181	-41%	-$722K	0.06%	146
2018 Q1	$1.37M	Sell	280,000 -70,000	-20%	-$259K	0.05%	151
2017 Q4	$989K	Hold	350,000	–	–	0.04%	146
2017 Q3	$1.03M	Hold	350,000	–	–	0.04%	136
2017 Q2	$1.1M	Hold	350,000	–	–	0.04%	129
2017 Q1	$1.4M	Sell	350,000 -350,000	-50%	-$2.75M	0.05%	121
2016 Q4	$5.39M	Hold	700,000	–	–	0.23%	77
2016 Q3	$5.67M	Buy	+700,000	New	+$5.41M	0.22%	80

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Tekla Capital Management's XENE Position: Q2 2023 in Review

Tekla Capital Management reduced its Xenon Pharmaceuticals (XENE) stake by 19% in Q2 2023, selling an estimated $644K and leaving 67,506 shares worth $2.6M. The position accounts for 0.1% of the portfolio, ranked #104.

Tekla Capital Management first reported a position in XENE in Q3 2016 and has held it in 17 quarters since. The position peaked at $5.67M in Q3 2016. 175 funds tracked by Wall St. Rank hold XENE as of Q2 2023.

Tekla Capital Management held 67,506 shares of Xenon Pharmaceuticals worth $2.6M as of Q2 2023.
Tekla Capital Management sold 16,208 Xenon Pharmaceuticals shares in Q2 2023, an estimated $644K.
Xenon Pharmaceuticals made up 0.1% of Tekla Capital Management's portfolio in Q2 2023, its #104 holding.
Tekla Capital Management first reported a position in Xenon Pharmaceuticals in Q3 2016 and has held it in 17 quarters since.
Tekla Capital Management's Xenon Pharmaceuticals position peaked at $5.67M in Q3 2016.
175 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.